Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?

Investors need to pay close attention to CTKB stock based on the movements in the options market lately.

Zacks Investment Research • Sep 17, 2026

Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

FREMONT, Calif., and HAMBURG, Germany, Sept.

GlobeNewsWire • Sep 9, 2026

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course.

GlobeNewsWire • Sep 3, 2026

Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.

GlobeNewsWire • Sep 1, 2026

Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding

FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek's favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of $20 million in lost profits and $36 million in royalties. Cytek intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award.

GlobeNewsWire • Aug 21, 2026

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Cytek Biosciences Q2 Earnings Call Highlights

Cytek Biosciences NASDAQ: CTKB reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth.

MarketBeat • Aug 6, 2026

Cytek Biosciences Reports Second Quarter 2026 Financial Results

FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026.

GlobeNewsWire • Aug 5, 2026

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.01 per share a year ago.

Zacks Investment Research • Aug 5, 2026